Academic Journal
Q1Lancet Diabetes and Endocrinology
About Lancet Diabetes and Endocrinology
Lancet Diabetes and Endocrinology is a scholarly journal published by Elsevier Ltd. SCImago 2025 places it in Q1 with an SJR of 11.61 and an H-index of 207.
Its listed coverage is 2013-2026 and its research categories include Endocrinology (Q1); Endocrinology, Diabetes and Metabolism (Q1); Internal Medicine (Q1). The 2025 dataset reports 194 documents and 6586 citations across the latest three-year reporting window.
The Lancet Diabetes & Endocrinology is a prestigious, peer-reviewed medical journal dedicated to publishing high-quality research, reviews, and expert opinions in the field of diabetes, endocrinology, and metabolism. As part of The Lancet family of journals, it is renowned for its commitment to advancing medical knowledge and improving patient care worldwide.
Overview and Scope
Launched in 2013, The Lancet Diabetes & Endocrinology has established itself as a top-tier journal in endocrinology and diabetes research. The journal covers a broad spectrum of topics, including but not limited to:- Diabetes mellitus (Type 1 and Type 2)
- Obesity and metabolic disorders
- Thyroid disorders
- Hormonal imbalances and endocrine system diseases
- Osteoporosis and bone metabolism
- Pituitary and adrenal gland disorders
- Innovative treatments and clinical trials
Impact Factor and Reputation
The Lancet Diabetes & Endocrinology boasts a high impact factor, making it one of the most influential journals in the field. The journal’s rigorous peer-review process ensures that only the most scientifically sound and clinically relevant research is published. Its reputation attracts contributions from leading scientists, endocrinologists, and diabetes specialists across the globe.Types of Publications
The journal publishes various types of content, including:- Original research articles featuring groundbreaking studies
- Review articles that summarize key findings in endocrinology
- Editorials and expert opinions from top medical professionals
- Case studies and clinical practice guidelines
- Correspondence and commentaries discussing recent developments in the field
Why The Lancet Diabetes & Endocrinology Matters
With the increasing prevalence of diabetes and metabolic disorders worldwide, research in this field is more crucial than ever. The journal plays a significant role in bridging the gap between scientific discovery and clinical application, ensuring that new treatments and management strategies reach patients faster. Moreover, it provides healthcare professionals with evidence-based insights to enhance patient outcomes, making it an essential resource for endocrinologists, diabetologists, researchers, and policy-makers alike.SEO Benefits of Researching The Lancet Diabetes & Endocrinology
For those in the medical and academic fields, keeping up with The Lancet Diabetes & Endocrinology can offer valuable insights into emerging trends in diabetes and endocrinology. Incorporating research from this journal into articles, blogs, and medical websites can help enhance credibility and boost search rankings.Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The Lancet Diabetes & Endocrinology is a prestigious peer-reviewed journal dedicated to publishing high-impact research on diabetes, endocrinology, and metabolism. As part of The Lancet family, it is widely recognized for its rigorous editorial process and cutting-edge scientific contributions. This journal plays a crucial role in shaping global medical advancements by providing insights into diabetes care, hormone-related disorders, and metabolic diseases.
Key Focus Areas The Lancet Diabetes & Endocrinology covers a wide range of topics that are vital to both medical professionals and researchers. Some of the primary areas of focus include:- Diabetes Research: Studies on Type 1 and Type 2 diabetes, prevention strategies, innovative treatments, and patient management approaches.
- Endocrine Disorders: Research on thyroid diseases, adrenal disorders, pituitary gland dysfunction, and hormonal imbalances.
- Metabolism and Obesity: Insights into metabolic syndromes, obesity-related complications, and new treatment modalities.
- Cardiovascular and Renal Implications: Examining the link between diabetes, endocrine diseases, and complications affecting the heart and kidneys.
- Clinical Trials and Innovations: Publishing groundbreaking clinical studies and advancements in pharmaceutical treatments, surgical interventions, and lifestyle modifications.
- High-Impact Factor: It consistently ranks among the top journals in endocrinology and diabetes research.
- Global Reach: With contributions from experts across the world, it fosters international collaboration in medical research.
- Rigorous Peer-Review Process: Ensuring the credibility and quality of published studies.
- Practical Implications: Research findings in this journal directly contribute to patient care, new treatments, and healthcare policies.
- Personalized Medicine: Tailoring diabetes treatment based on genetic and lifestyle factors.
- Artificial Intelligence in Healthcare: AI-driven diagnostic tools and predictive analytics for better disease management.
- Innovative Drug Therapies: Development of new insulin formulations, SGLT2 inhibitors, and GLP-1 receptor agonists.
- Telemedicine and Remote Patient Monitoring: Expanding access to diabetes care through digital health solutions.
Recent Research Articles
Latest publications matched automatically by ISSN.
Diabetes in a warming world
The Lancet Diabetes & Endocrinology
2026-10 · DOI: 10.1016/s2213-8587(26)00217-2Type 2 diabetes management: weekly combination therapy comes of age?
Srikanth Bellary, Muhammad Ali Karamat, Anthony H Barnett
2026-10 · DOI: 10.1016/s2213-8587(26)00165-8Time for personalised incretin titration
Roman Vangoitsenhoven, Bart Van der Schueren, Chantal Mathieu, Christophe De Block et al.
2026-10 · DOI: 10.1016/s2213-8587(26)00212-3Redrawing the lines for the management of obesity in Asia
Bernard Khoo
2026-10 · DOI: 10.1016/s2213-8587(26)00155-5Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis
Johannes F E Mann, Sunil V Badve, Florian M M Baeres, Nicolas Belmar et al.
2026-10 · DOI: 10.1016/s2213-8587(26)00134-8Type 1 diabetes in older populations
Anna R Kahkoska, Peter K Yang, Joshua J Neumiller, Anastasia-Stefania Alexopoulos et al.
2026-10 · DOI: 10.1016/s2213-8587(26)00154-3Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial
Linong Ji, Malik Benamar, Viswanathan Mohan, Laura Pletsch-Borba et al.
2026-10 · DOI: 10.1016/s2213-8587(26)00136-1Toxic chemicals: the fight for planetary health
Talha Burki
2026-10 · DOI: 10.1016/s2213-8587(26)00215-9Less can be more: the 2026 Endocrine Society Guideline for precision care in central precocious puberty
Sasha R Howard
2026-10 · DOI: 10.1016/s2213-8587(26)00193-2Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial
Daisuke Yabe, Toshihiko Shiraiwa, Hiroyuki Ugai, Masakazu Takeuchi et al.
2026-10 · DOI: 10.1016/s2213-8587(26)00138-5Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial
Lixin Guo, Xiaolei Bao, Kuo-Chin Huang, Kristoffer Jensen Kolnes et al.
2026-10 · DOI: 10.1016/s2213-8587(26)00133-6Safety and tolerability of orforglipron in Japanese people with type 2 diabetes
Michael A Nauck, Michael Horowitz
2026-10 · DOI: 10.1016/s2213-8587(26)00182-8ADA Scientific Sessions 2026: a line crossed
Talha Burki
2026-09 · DOI: 10.1016/s2213-8587(26)00161-0Soaring GLP-1 receptor agonist use
The Lancet Diabetes & Endocrinology
2026-09 · DOI: 10.1016/s2213-8587(26)00194-4Insulin and health systems in global low-resource settings
Sze May Ng
2026-09 · DOI: 10.1016/s2213-8587(26)00128-2Hypoparathyroidism: translating science from the laboratory to the clinic
Maria Luisa Brandi, Hajar AbuAlrob, Wenhan Chang, Bart L Clarke et al.
2026-09 · DOI: 10.1016/s2213-8587(26)00188-9Energy drink ban: putting children's health first
The Lancet Diabetes & Endocrinology
2026-09 · DOI: 10.1016/s2213-8587(26)00195-6Temporal changes in cortisol secretion and their association with long-term outcomes in benign adrenal incidentalomas: a retrospective cohort study
Onnicha Suntornlohanakul, Giuseppe Reimondo, Marco Ghislieri, Luigi Petramala et al.
2026-09 · DOI: 10.1016/s2213-8587(26)00098-7Human versus analogue insulin for children and young adults with type 1 diabetes in low-resource settings (HumAn-1): a multicentre, open-label, randomised controlled trial
Jing Luo, Sylvia Kehlenbrink, Chung-Chou H Chang, Christina M Lalama et al.
2026-09 · DOI: 10.1016/s2213-8587(26)00097-5Goal-directed osteoporosis treatment: are bone mineral density targets valid?
Ian R Reid
2026-09 · DOI: 10.1016/s2213-8587(26)00123-3Reviews
Community Reviews
Version History
April 16, 2025 at 10:58 am
April 2, 2025